<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04630847</url>
  </required_header>
  <id_info>
    <org_study_id>VCT-1</org_study_id>
    <nct_id>NCT04630847</nct_id>
  </id_info>
  <brief_title>Familial Fecal Microbiota Transplant for the Treatment of Subjects With Autism Spectrum Disorders</brief_title>
  <official_title>An Open-Label Phase I Trial of Vancomycin Followed by Familial Fecal Microbiota Transplant in Minor and Adult Subjects With Autism Spectrum Disorder (ASD) for Treatment of Social Deficits and Language Delays.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ProgenaBiome</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ventura Clinical Trials</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>ProgenaBiome</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label clinical trial to evaluate the benefits of familial fecal microbiota&#xD;
      transplant following a 6-week treatment with Vancomycin in minor and adult subjects with ASD&#xD;
      for treatment of social deficits and language delays.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label clinical trial to evaluate the benefits of familial fecal microbiota&#xD;
      transplant following a 6-week treatment with Vancomycin in minor and adult subjects with ASD&#xD;
      for treatment of social deficits and language delays. Participants are given FMT by&#xD;
      colonoscopy&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>52 Weeks</time_frame>
    <description>Number of participants with grade III or higher adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serious Adverse Events</measure>
    <time_frame>52 Weeks</time_frame>
    <description>Number of participants with serous adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ATEC</measure>
    <time_frame>52 Weeks</time_frame>
    <description>Number of participants with changes in the Autism Treatment Evaluation Checklist scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CARS-2</measure>
    <time_frame>52 Weeks</time_frame>
    <description>Number of participants with changes in Childhood Autism Rating Scale 2 scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QoLA</measure>
    <time_frame>52 Weeks</time_frame>
    <description>Number of participants with changes in Quality of Life Autism scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SRS-II</measure>
    <time_frame>52 Weeks</time_frame>
    <description>Number of participants with changes in Social Responsiveness Scale scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Shannon Diversity Index</measure>
    <time_frame>52 Weeks</time_frame>
    <description>Changes in Shannon Diversity index compared between pre and post FMT scores</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Autism</condition>
  <condition>Autism Spectrum Disorder</condition>
  <arm_group>
    <arm_group_label>Autism Subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>These subjects will be administered fecal microbiota transplant by colonoscopy</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fecal Microbiota Transplant</intervention_name>
    <description>FMT utilizing stool from first degree relatives</description>
    <arm_group_label>Autism Subjects</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject at least two years of age.&#xD;
&#xD;
          2. Subject has confirmed diagnosis of ASD based on the DSM-V.&#xD;
&#xD;
          3. Subject with ASD whose parents/caregiver/guardian/LAR can complete informed consent&#xD;
             process.&#xD;
&#xD;
          4. A reliable parent or caregiver who can report the side effects and communicate&#xD;
             effectively with the research team.&#xD;
&#xD;
          5. Stable medications during the two months prior to enrollment.&#xD;
&#xD;
          6. Currently receiving interventions in the community or school for ASD.&#xD;
&#xD;
          7. If male, and partner is of childbearing potential, must be willing to utilize at least&#xD;
             one highly effective method of birth control for the duration of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Female subjects who are pregnant, nursing, or intend to become pregnant during the&#xD;
             study period.&#xD;
&#xD;
          2. Subjects whose caregivers are unable/unwilling to cooperate with the protocol&#xD;
             requirements.&#xD;
&#xD;
          3. Subject will be excluded who are suffering with Rett syndrome and Childhood&#xD;
             Disintegrative Disorder.&#xD;
&#xD;
          4. Other serious co-morbid medical disorders affecting brain function and behaviour,&#xD;
             including uncontrolled seizures.&#xD;
&#xD;
          5. Subjects unable to refrain from taking non-study antibiotics for the period of the&#xD;
             study.&#xD;
&#xD;
          6. Subjects diagnosed with cancer, except small localized basal cell carcinoma.&#xD;
&#xD;
          7. Subjects known to abuse alcohol or drugs.&#xD;
&#xD;
          8. Subjects who have undergone gastric bypass or total colectomy, or who are scheduled&#xD;
             for these procedures.&#xD;
&#xD;
          9. Infection with HIV.&#xD;
&#xD;
         10. Infection with Hepatitis B or C.&#xD;
&#xD;
         11. Hepatic values greater than 20&#xD;
&#xD;
         12. Allergy to benzodiazepine.&#xD;
&#xD;
         13. Inability to stop loperamide, diphenoxylatye/atropine, or cholestyramine before the&#xD;
             study&#xD;
&#xD;
         14. Unable to stop opiate treatment unless on a stable dose including PRN dosing, and no&#xD;
             dose increase planned for the duration of the study&#xD;
&#xD;
         15. Known positive stool cultures for enteropathogens including, but not limited to&#xD;
             Shigella, Salmonella, and Campylobacter within 30 days before enrollment.&#xD;
&#xD;
         16. Known stool studies positive for ova and/or parasites in 30 days prior to enrollment.&#xD;
&#xD;
         17. Planned travel outside United States during study period.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sabine Hazan, MD</last_name>
    <role>Study Director</role>
    <affiliation>ProgenaBiome</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sabine Hazan, MD</last_name>
    <phone>18053390549</phone>
    <email>drsabinehazan@progenabiome.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jordan Daniels, MS</last_name>
    <phone>18053390549</phone>
    <email>jordan@progenabiome.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>ProgenaBiome</name>
      <address>
        <city>Ventura</city>
        <state>California</state>
        <zip>93003</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Sabine Hazan, MD</last_name>
      <phone>805-339-0549</phone>
      <email>drsabinehazan@progenabiome.com</email>
    </contact>
    <contact_backup>
      <last_name>Jordan Daniels, MS</last_name>
      <phone>805-339-0549</phone>
      <email>jordan@progenabiome.com</email>
    </contact_backup>
    <investigator>
      <last_name>Sabine Hazan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>November 11, 2020</study_first_submitted>
  <study_first_submitted_qc>November 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2020</study_first_posted>
  <last_update_submitted>September 2, 2021</last_update_submitted>
  <last_update_submitted_qc>September 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Autistic Disorder</mesh_term>
    <mesh_term>Autism Spectrum Disorder</mesh_term>
    <mesh_term>Child Development Disorders, Pervasive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

